Black Diamond Therapeutics Presents Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium

Ads

You May Also Like

Rexahn Reports Second Quarter 2018 Financial Results

ROCKVILLE, Md., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), ...

UroGen Pharma Reports Second Quarter 2017 Financial Results and Recent Corporate Developments

Completed Initial Public Offering Raising $66.9 Million in Gross Proceeds Continuing Enrollment of Patients ...